VitaSpring Biomedical Co. Ltd.
VSBC
$1.00
$0.000.00%
OTC PK
| 04/30/2023 | 10/31/2022 | 07/31/2022 | 07/31/2022 | 04/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | 109.87% | 138.40% | 138.40% | 740.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 109.87% | 138.40% | 138.40% | 740.08% |
| Cost of Revenue | -- | 77.68% | 111.47% | 111.47% | 871.44% |
| Gross Profit | -- | 184.77% | 195.87% | 195.87% | 579.60% |
| SG&A Expenses | -- | 11.18% | 28.66% | 29.32% | 15.98% |
| Depreciation & Amortization | -- | 850.00% | 1,325.00% | 850.00% | -- |
| Other Operating Expenses | -- | 33.33% | -63.64% | -63.64% | -12.50% |
| Total Operating Expenses | -- | 56.98% | 86.94% | 86.96% | 360.29% |
| Operating Income | -- | 2,398.63% | 2,127.01% | 2,126.28% | 672.36% |
| Income Before Tax | -- | 2,334.03% | 2,225.57% | 2,225.57% | 672.67% |
| Income Tax Expenses | -- | 536.94% | 617.94% | 617.94% | 671.76% |
| Earnings from Continuing Operations | -- | 27,429.41% | 758.39% | 758.39% | 672.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 27,429.41% | 758.39% | 758.39% | 672.93% |
| EBIT | -- | 2,398.63% | 2,127.01% | 2,126.28% | 672.36% |
| EBITDA | -- | 624.98% | 1,093.17% | 1,092.85% | 454.86% |
| EPS Basic | -- | 2,150.00% | 1,400.00% | 1,400.00% | 346.15% |
| Normalized Basic EPS | -- | 3,500.00% | 3,700.00% | 3,700.00% | 383.33% |
| EPS Diluted | -- | 2,150.00% | 1,400.00% | 1,400.00% | 346.15% |
| Normalized Diluted EPS | -- | 3,500.00% | 3,700.00% | 3,700.00% | 383.33% |
| Average Basic Shares Outstanding | -- | -5.12% | 14.64% | 14.64% | 45.42% |
| Average Diluted Shares Outstanding | -- | -5.12% | 14.64% | 14.64% | 45.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |